{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:19:12Z","timestamp":1787008752320,"version":"build-2736575974"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Programme Hospitalier de Recherche Clinique","award":["PHRC14-1005"],"award-info":[{"award-number":["PHRC14-1005"]}]},{"name":"French Ministry of Health"},{"name":"Bayer France and Biosensors"},{"DOI":"10.13039\/501100002738","name":"Assistance Publique \u2014 H\u00f4pitaux de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Despite current antithrombotic treatments, the recurrence of ischaemic events remains high in patients with diabetes mellitus (DM) or aspirin resistance after acute coronary syndrome (ACS). Whether twice-daily aspirin dosing reduces major adverse cardiovascular events (MACE) in this population remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective multicentre, randomized trial, patients with ACS and DM or high-risk of aspirin resistance (HRAR) defined as: (i) an index event occurring while on aspirin; (ii) body mass index \u226527\u2005kg\/m2; or (iii) increased waist circumference were assigned to receive enteric-coated aspirin once daily (100\u2005mg\/day) or twice daily (100\u2005mg morning and evening). The primary outcome was MACE, a composite of any death, myocardial infarction, stroke, urgent coronary revascularization, stent thrombosis, or acute arterial thrombotic event assessed using a time-to-first-event analysis. The main secondary outcome was major bleeding (Bleeding Academic Research Consortium type 3\u20135).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 2484 participants were enrolled (77.2% with DM, 55.5% with ST-elevation segment myocardial infarction). The median follow-up duration was 18 (interquartile range: 17.6\u201318.3) months. The primary outcome occurred in 95 of 1228 participants (7.7%) in the twice-daily aspirin group, and 110 of 1256 (8.8%) in the once-daily group (hazard ratio [HR] 0.90; 95% confidence interval [CI] 0.69\u20131.19; P = .42). Major bleeding rates were similar between the groups (1.9% vs 2.1%; HR 0.88; 95% CI 0.50\u20131.55).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with ACS and DM or HRAR, twice-daily aspirin did not significantly reduce the risk of MACE compared to once-daily dosing. No significant difference was observed in major bleeding between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>NCT02520921\/EUDRACT No: 2015-000947-18.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf680","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:21:44Z","timestamp":1755516104000},"page":"719-730","source":"Crossref","is-referenced-by-count":4,"title":["Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0604-1976","authenticated-orcid":false,"given":"Jean-Guillaume","family":"Dillinger","sequence":"first","affiliation":[{"name":"Department of Cardiology, H\u00f4pital Lariboisi\u00e8re, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Inserm MASCOT\u2014UMRS 942 , 2 Rue Ambroise Par\u00e9, Paris 75010 ,","place":["France"]},{"name":"MIRACL.ai Laboratory, Multimodality Imaging for Research and Artificial Intelligence Core Laboratory, University Hospital of Lariboisiere (AP-HP) , Paris 75010 ,","place":["France"]},{"name":"CREATIF, Centre de R\u00e9f\u00e9rence et d\u2019Education des Antithrombotiques d\u2019Ile de France, H\u00f4pital Lariboisi\u00e8re, Assistance Publique-H\u00f4pitaux de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9o","family":"Pezel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, H\u00f4pital Lariboisi\u00e8re, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Inserm MASCOT\u2014UMRS 942 , 2 Rue Ambroise Par\u00e9, Paris 75010 ,","place":["France"]},{"name":"MIRACL.ai Laboratory, Multimodality Imaging for Research and Artificial Intelligence Core Laboratory, University Hospital of Lariboisiere (AP-HP) , Paris 75010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Batias","sequence":"additional","affiliation":[{"name":"Centre Hospitalier M\u00e9tropole Savoie, Service de Cardiologie , Place Lucien Biset, Chamb\u00e9ry 73000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Angoulvant","sequence":"additional","affiliation":[{"name":"Cardiology Department, CHU Tours, INSERM Unit\u00e9 1327 ISCHEMIA, Universit\u00e9 de Tours , Tours ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Goralski","sequence":"additional","affiliation":[{"name":"Cardiology Department, CHU Orl\u00e9ans , Orl\u00e9ans ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8233-6039","authenticated-orcid":false,"given":"Emile","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Cardiology Department, Pasteur University Hospital , Nice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cayla","sequence":"additional","affiliation":[{"name":"Cardiology Department, Nimes University Hospital, Montpellier University, ACTION Study Group , Nimes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Silvain","sequence":"additional","affiliation":[{"name":"ACTION Study Group, Sorbonne Universit\u00e9, INSERM UMRS1166, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (AP-HP) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Gilard","sequence":"additional","affiliation":[{"name":"Chest Diseases, CHU Brest, INSERM U1304, Univ Brest , Brest ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2917-9273","authenticated-orcid":false,"given":"Gilles","family":"Lemesle","sequence":"additional","affiliation":[{"name":"Heart and Lung Institute, University Hospital of Lille, CHU Lille , Lille F-59000 ,","place":["France"]},{"name":"Medical School, University of Lille, Lille \u00a0 F-59000 ,","place":["France"]},{"name":"Institut Pasteur of Lille, Inserm U1011-EGID , Lille F-59000 ,","place":["France"]},{"name":"FACT (French Alliance for Cardiovascular Trials) , Paris F-75000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raud","family":"Souteyrand","sequence":"additional","affiliation":[{"name":"Institut Pascal, Th\u00e9rapies Guid\u00e9es par l'Image, CNRS SIGMA UCA UMR 6602 University Hospital Gabriel Montpied , Clermont-Ferrand ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7576-2673","authenticated-orcid":false,"given":"Pascal","family":"Lim","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, Univ Paris Est Cr\u00e9teil, INSERM, IMRB, AP-HP, H\u00f4pital Universitaire Henri-Mondor , Cr\u00e9teil F-94010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Roubille","sequence":"additional","affiliation":[{"name":"PhyMedExp, Cardiology Department, Universit\u00e9 de Montpellier, INSERM, CNRS, INI-CRT, CHU de Montpellier , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Georges","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, Cardiologie Interventionnelle, Centre Hospitalier de Versailles, H\u00f4pital Andr\u00e9 Mignot , Le Chesnay-Rocquencourt ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bal dit Sollier","sequence":"additional","affiliation":[{"name":"CREATIF, Centre de R\u00e9f\u00e9rence et d\u2019Education des Antithrombotiques d\u2019Ile de France, H\u00f4pital Lariboisi\u00e8re, Assistance Publique-H\u00f4pitaux de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Petroni","sequence":"additional","affiliation":[{"name":"Cardiology Department, Clinique Pont de Chaume , Montauban ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6359-1328","authenticated-orcid":false,"given":"Olivier","family":"Morel","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Nouvel H\u00f4pital Civil, Strasbourg University Hospital, UR 3074 Translational CardioVascular Medicine CRBS , Strasbourg ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Delarche","sequence":"additional","affiliation":[{"name":"Cardiology Department, H\u00f4pital Fran\u00e7ois Mitterrand , Pau ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meier","family":"Elbaz","sequence":"additional","affiliation":[{"name":"Center for Clinical Investigation (CIC1436)\/CARDIOMET, Rangueil University Hospital , Toulouse 31400 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0533-9682","authenticated-orcid":false,"given":"Etienne","family":"Puymirat","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00f4pital Europ\u00e9en Georges Pompidou , Paris 75015 ,","place":["France"]},{"name":"Facult\u00e9 de Sant\u00e9, Universit\u00e9 Paris Cit\u00e9 , Paris 75006 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Toupin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, H\u00f4pital Lariboisi\u00e8re, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Inserm MASCOT\u2014UMRS 942 , 2 Rue Ambroise Par\u00e9, Paris 75010 ,","place":["France"]},{"name":"MIRACL.ai Laboratory, Multimodality Imaging for Research and Artificial Intelligence Core Laboratory, University Hospital of Lariboisiere (AP-HP) , Paris 75010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[{"name":"ACTION Study Group, Sorbonne Universit\u00e9, INSERM UMRS1166, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (AP-HP) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Drouet","sequence":"additional","affiliation":[{"name":"CREATIF, Centre de R\u00e9f\u00e9rence et d\u2019Education des Antithrombotiques d\u2019Ile de France, H\u00f4pital Lariboisi\u00e8re, Assistance Publique-H\u00f4pitaux de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-8557","authenticated-orcid":false,"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Recherche Clinique, ACTION Group, H\u00f4pital Fernand Widal (AP-HP) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Henry","sequence":"additional","affiliation":[{"name":"Department of Cardiology, H\u00f4pital Lariboisi\u00e8re, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Inserm MASCOT\u2014UMRS 942 , 2 Rue Ambroise Par\u00e9, Paris 75010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ANDAMAN Investigators of the ACTION Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aboyans","family":"Victor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angoulvant","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batias","family":"Laure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belle","family":"Loic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bellemain-Appaix","family":"Anne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benamer","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beygui","family":"Farzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bihry","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnefoy-Cudraz","family":"Eric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brunel","family":"Philippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Didier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cayla","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chague","family":"Fr\u00e9d\u00e9ric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coste","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cottin","family":"Yves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuisset","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delarche","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derimay","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dib","family":"Jean Claude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dillinger","family":"Jean-Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ducrocq","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elbaz","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferrari","family":"Emile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Jean-Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilard","family":"Martine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goralski","family":"Marc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goube","family":"Pascal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauguel-Moreau","family":"Marie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houssany-Pissot","family":"Sonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lebreton","family":"Herv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lemesle","family":"Gilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lim","family":"Pascal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maillard","family":"Loic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell-Heggs","family":"Laurens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montalescot","family":"Gilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morel","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petroni","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pezel","family":"Th\u00e9o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prunier","family":"Fabrice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puymirat","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roubille","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanguineti","family":"Francesca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Schiele","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvain","family":"Johanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souteyrand","family":"Geraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steg","family":"Philippe Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tron","family":"Christophe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varenne","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"2026021113022150700_ehaf680-B1","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"2026021113022150700_ehaf680-B2","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021113022150700_ehaf680-B3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","journal-title":"BMJ"},{"key":"2026021113022150700_ehaf680-B4","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists\u2019 (ATT) Collaboration","year":"2009","journal-title":"Lancet"},{"key":"2026021113022150700_ehaf680-B5","doi-asserted-by":"publisher","first-page":"3A","DOI":"10.1016\/0735-1097(88)92635-6","article-title":"Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"12","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"2026021113022150700_ehaf680-B6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1001\/jamacardio.2024.4335","article-title":"Aspirin for secondary prevention of atherosclerosis-evidence or dogma?","volume":"10","author":"Cleland","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026021113022150700_ehaf680-B7","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur Heart J"},{"key":"2026021113022150700_ehaf680-B8","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","article-title":"Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"2026021113022150700_ehaf680-B9","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N Engl J Med"},{"key":"2026021113022150700_ehaf680-B10","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"Hankey","year":"2006","journal-title":"Lancet"},{"key":"2026021113022150700_ehaf680-B11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.amjcard.2006.10.023","article-title":"Impact of the metabolic syndrome on the clinical outcomes of non-clinically diagnosed diabetic patients with acute coronary syndrome","volume":"99","author":"Feinberg","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026021113022150700_ehaf680-B12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1467-789X.2011.00930.x","article-title":"Platelet activation in obesity and metabolic syndrome","volume":"13","author":"Santilli","year":"2012","journal-title":"Obes Rev"},{"key":"2026021113022150700_ehaf680-B13","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/j.1538-7836.2012.04723.x","article-title":"The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes","volume":"10","author":"Rocca","year":"2012","journal-title":"J Thromb Haemost"},{"key":"2026021113022150700_ehaf680-B14","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1160\/TH10-02-0082","article-title":"24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease","volume":"105","author":"Henry","year":"2011","journal-title":"Thromb Haemost"},{"key":"2026021113022150700_ehaf680-B15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1161\/CIRCINTERVENTIONS.110.960187","article-title":"Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease","volume":"4","author":"Capodanno","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"2026021113022150700_ehaf680-B16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jacc.2016.11.049","article-title":"Type 2 diabetes, obesity, and aspirin responsiveness","volume":"69","author":"Patrono","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026021113022150700_ehaf680-B17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jacc.2016.11.050","article-title":"Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus","volume":"69","author":"Bhatt","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026021113022150700_ehaf680-B18","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"2026021113022150700_ehaf680-B19","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"CURRENT-OASIS 7 Investigators","year":"2010","journal-title":"N Engl J Med"},{"key":"2026021113022150700_ehaf680-B20","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ahj.2012.06.008","article-title":"Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease","volume":"164","author":"Dillinger","year":"2012","journal-title":"Am Heart J"},{"key":"2026021113022150700_ehaf680-B21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ahj.2025.04.016","article-title":"Twice-a-day administration of aspirin in patients with diabetes mellitus or aspirin resistance after acute coronary syndrome: rationale and design of the randomized ANDAMAN trial","volume":"288","author":"Dillinger","year":"2025","journal-title":"Am Heart J"},{"key":"2026021113022150700_ehaf680-B22","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","year":"2012","journal-title":"Eur Heart J"},{"key":"2026021113022150700_ehaf680-B23","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"2026021113022150700_ehaf680-B24","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.2020.1267","article-title":"Why test for proportional hazards?","volume":"323","author":"Stensrud","year":"2020","journal-title":"JAMA"},{"key":"2026021113022150700_ehaf680-B25","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.4274","article-title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt","volume":"30","author":"Royston","year":"2011","journal-title":"Stat Med"},{"key":"2026021113022150700_ehaf680-B26","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1161\/CIRCULATIONAHA.108.768283","article-title":"Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk","volume":"118","author":"Eikelboom","year":"2008","journal-title":"Circulation"},{"key":"2026021113022150700_ehaf680-B27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1160\/TH11-04-0216","article-title":"Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications","volume":"106","author":"Spectre","year":"2011","journal-title":"Thromb Haemost"},{"key":"2026021113022150700_ehaf680-B28","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/ajh.27418","article-title":"Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: the ARES trial","volume":"99","author":"Rocca","year":"2024","journal-title":"Am J Hematol"},{"key":"2026021113022150700_ehaf680-B29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40256-020-00409-x","article-title":"Once- versus twice-daily aspirin in patients at high risk of thrombotic events: systematic review and meta-analysis","volume":"21","author":"Mainoli","year":"2021","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"},{"key":"2026021113022150700_ehaf680-B30","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1093\/eurheartj\/ehm226","article-title":"A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease","volume":"28","author":"Lordkipanidz\u00e9","year":"2007","journal-title":"Eur Heart J"},{"key":"2026021113022150700_ehaf680-B31","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"ASCEND Study Collaborative Group","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021113022150700_ehaf680-B32","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021113022150700_ehaf680-B33","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1161\/CIRCULATIONAHA.119.044142","article-title":"No modulation of the effect of aspirin by body weight in healthy older men and women","volume":"141","author":"Woods","year":"2020","journal-title":"Circulation"},{"key":"2026021113022150700_ehaf680-B34","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"2026021113022150700_ehaf680-B35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(18)31133-4","article-title":"Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials","volume":"392","author":"Rothwell","year":"2018","journal-title":"Lancet"},{"key":"2026021113022150700_ehaf680-B36","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative effectiveness of aspirin dosing in cardiovascular disease","volume":"384","author":"Jones","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021113022150700_ehaf680-B37","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jama.1980.03300330019023","article-title":"A randomized, controlled trial of aspirin in persons recovered from myocardial infarction","volume":"243","year":"1980","journal-title":"JAMA"},{"key":"2026021113022150700_ehaf680-B38","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/0140-6736(92)92619-Q","article-title":"Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group","volume":"340","author":"Juul-M\u00f6ller","year":"1992","journal-title":"Lancet"},{"key":"2026021113022150700_ehaf680-B39","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"2026021113022150700_ehaf680-B40","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"2026021113022150700_ehaf680-B41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021113022150700_ehaf680-B42","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/eurheartj\/ehad876","article-title":"Aspirin-free antiplatelet strategies after percutaneous coronary interventions","volume":"45","author":"Capranzano","year":"2024","journal-title":"Eur Heart J"},{"key":"2026021113022150700_ehaf680-B43","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jamacardio.2023.3364","article-title":"Effectiveness and safety of enteric-coated vs uncoated aspirin in patients with cardiovascular disease: a secondary analysis of the ADAPTABLE randomized clinical trial","volume":"8","author":"Sleem","year":"2023","journal-title":"JAMA Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/6\/719\/64159327\/ehaf680.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/6\/719\/64159327\/ehaf680.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:02:27Z","timestamp":1770832947000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/6\/719\/8243742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,8,30]]},"published-print":{"date-parts":[[2026,2,11]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf680","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,7]]},"published":{"date-parts":[[2025,8,30]]}}}